About US
Contact us
-
Sanofi CEO's strategy blueprint may include consumer health spinoff or merger: BloombergSanofi CEO Paul Hudson has been on the job for just over two months, and he's prepping for a big strategy reveal next month. One thing that might be behind that curtain? A sale or spinoff of the comp2019/11/18
-
Novo Nordisk CEO Jørgensen aims to leverage diabetes know-how, deals into the new decadeNovo Nordisk, the world's biggest insulin producer,has set itself an unaccustomed task: Expand beyond diabetes. Wednesday, it outlined just how it plans to do that and how it plans to measure its pro2019/11/15
-
Alnylam wins FDA nod for $575,000 liver med Givlaari despite safety flagsAlnylam is facing a major challenger to its first approved drug, Onpattro, from Pfizer's Vyndaqel just over a year into its launch. But the company now has another drug approval to bolster its portfo2019/11/15
-
Bristol's Opdivo-Yervoy combo fails to top Opdivo in adjuvant melanomaBristol-Myers Squibb’s Opdivo-Yervoy combo has changed the game in late-stage melanoma, but it's hit a roadblock in expanding to post-surgery treatment. In patients withadvanced cancer but no evidenc2019/11/14
-
FDA Commissioner nominee Hahn promises to put science above politicsThe would-be replacement for departed FDA Commissioner Scott Gottlieb faced a Senate committee's grilling Wednesday, and he supported drug-pricing action—and science. During the hearing of the U.S. S2019/11/14
-
Teva forecasts 'tenfold' growth for new launch Austedo. Why don't analysts agree?Riding high on the launch of Huntingson's disease and tardive dyskinesia (TD) med Austedo, Teva is looking for "tenfold" patient growth in the drug's future, CEO Kare Schultz said. But analysts aren'2019/11/13
-
Merck, Bayer's trial win for heart failure rival could actually boost Novartis' EntrestoNovartis' Entresto, the clear-cut market leader in heart failure,has been soul-searching since its highly touted trial in an untreated population fell flat. Now, a surprise competitor has cropped up—2019/11/13
-
Inside Purdue Pharma's media playbook: How it planted the opioid 'anti-story'This story is a collaboration betweenProPublicaandStat. In 2004, Purdue Pharma was facing a threat to sales of its blockbuster opioid painkiller OxyContin, which were approaching $2 billion a year. W2019/11/12
-
AZ, Merck and Novartis top Big Pharma's Q3 growth charts. Teva and Pfizer? Not so muchThe drug industryfaces no shortage of challenges, from pricing threats and payer clampdowns to stepped-up competition and supply shortages. But a look atthird-quarter numbersshows many top playersare2019/11/12
-
Sorry, Shkreli: Supreme Court rebuffs ex-pharma CEO's final appealMartin Shkreli, the disgraced former CEO of Retrophin currently serving a seven-year sentence for securities fraud and conspiracy, was hoping for a SCOTUS Hail Mary after multiple appeals fell flat.2019/11/11